Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.55 |
| ▸ | SRC | P12931 | 5/20 | 0.49 |
| ▸ | YES1 | P07947 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.47 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | AIMP2 | Q13155 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995311 | 0.89 | SRC (0.54) | LCKSRCYES1EGFRBTK | |
| SCHEMBL5995263 | 0.86 | SRC (0.54) | SRCMETKDR | |
| SCHEMBL2498345 | 0.86 | GAA (0.52) | SRCYES1EGFRBTKKDM4E | |
| SCHEMBL2498319 | 0.83 | SRC (0.49) | SRCYES1EGFRBTKSYK | |
| SCHEMBL2497853 | 0.82 | BTK (0.51) | LCKMAPK14SRCEGFRBTK | |
| SCHEMBL2494861 | 0.82 | MET (0.46) | SRCYES1EGFRBTKFGFR1 | |
| SCHEMBL5994756 | 0.82 | SRC (0.51) | LCKSRCYES1FGFR1SYK | |
| SCHEMBL2498311 | 0.82 | POLB (0.53) | SRCYES1EGFRBTKSYK | |
| SCHEMBL2494902 | 0.80 | BTK (0.56) | BTKSYK | |
| SCHEMBL2498478 | 0.80 | KDM4E (0.54) | SRCYES1EGFRBTKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | TARGEGEN INC. | 2011-10-06 | — | — | US | disclosed |
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247250-A1 | Pyrimidine inhibitors of kinases | DTYMK, SRC, DCK | LCK 4/4885MAPK14 401/4885SRC 2/4885 |
| US-20110243999-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF OCULAR DISORDERS | AQP3, AQP1, AQP4 | LCK 3952/4885MAPK14 3953/4885SRC 4062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.